Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium

Demarteau, Nadia; Kriekinge, Georges Van; Simon, Philippe

doi:10.1016/j.vaccine.2013.06.008

Cited by 18 publications

(18 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The discount rates for cost-effectiveness studies in the Netherlands are 4 and 1.5% for cost and health outcomes [28,29,62,63], respectively. Only few countries/studies implement a different discounting for costeffectiveness, for example, only studies performed in Taiwan [55] and Belgium [64] implemented a 3% annual discount rate for cost and 1.5% for utility. These studies were unique since most countries [65][66][67] implementd equal discount rates for both parameters in their economic studies.…”

Section: Discussion and Limitationmentioning

confidence: 99%

The cost–effectiveness of HPV vaccination in addition to screening: a Dutch perspective

Setiawan

Luttjeboer

Westra

et al. 2014

Expert Review of Vaccines

View full text Add to dashboard Cite

Addition of the HPV vaccine to available cytological screening has been proposed to increase HPV-related cancer prevention. A comprehensive review on this combined strategy implemented in the Netherlands is lacking. For this review, we therefore analyzed all relevant studies on cost-effectiveness of HPV vaccines in combination with cervical screening in the Netherlands. Most of the studies agree that vaccination in pre-sexual-activity periods of life is cost-effective. Based on published sensitivity analyses, the incremental cost-effectiveness ratio was found to be mainly driven by vaccine cost and discount rates. Fewer vaccine doses, inclusion of additional benefits of these vaccines to prevent HPV-related non-cervical cancers and vaccination of males to further reduce the burden of HPV-induced cancers are three relevant options suggested to be investigated in upcoming economic evaluations.

show abstract

Section: Discussion and Limitationmentioning

confidence: 99%

The cost–effectiveness of HPV vaccination in addition to screening: a Dutch perspective

Setiawan

Luttjeboer

Westra

et al. 2014

Expert Review of Vaccines

View full text Add to dashboard Cite

show abstract

“…Default values of quality of life weight at different health states are based on published literature, and the population at different health states is based on the Markov disease progress/regression model (Fig. 10) [20][21][22].…”

Section: Quality Of Lifementioning

confidence: 99%

The impact on women’s health and the cervical cancer screening budget of primary HPV screening with dual-stain cytology triage in Belgium

Tjalma

Kim

Vandeweyer

2017

European Journal of Obstetrics & Gynecology and Reproductiv

View full text Add to dashboard Cite

Dual stain cytology, or "diagnostic cytology", offers a significant increase in sensitivity compared to cytology, with a slight decrease in specificity. This can reduce additional investigations like colposcopies, biopsies, and follow-up visits. Cervical cancer screening for women between 25 and 65 years of age with diagnostic cytology is estimated to reduce the incidence of cervical cancer by 36% and reduce annual cervical cancer mortalities by 40%. The reduced number of screening visits and the decrease in incidence and mortality will improve quality of life. In this article, a model was created to evaluate the cost-effectiveness of diagnostic cytology for Belgium. In this approach, precancerous cells are more likely to be immediately identified during the first screening visit. This reduces both the number and frequency of follow-up visits required. After two cycles (6 years), the prevalence of CIN and cervical cancer is decreased significantly in the screened population. At a population level, these shifts can reduce the screening budget by 21%, resulting in savings of 5.3 million euro a year in Belgium. Diagnostic cytology benefits all stakeholders involved in cervical cancer screening.

show abstract

“…Of course, some studies about HPV vaccination of targeted groups have demonstrated economic value (Aponte-Gonzalez et al, 2013;Demarteau et al, 2013;Drolet et al, 2013;Elbasha et al, 2009;English et al, 2013;Fesenfeld et al, 2013;Kim et al, 2007;Natunen et al, 2013;Turner et al, 2013;Woertman and van der Wilt, 2013). However, the present study also considered the home environment when defining the socially vulnerable group.…”

Section: Discussionmentioning

confidence: 88%

Cost-Effectiveness Analysis of HPV Vaccination: Comparing the General Population with Socially Vulnerable Individuals

Han

Kim

Lee

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: After the WHO recommended HPV vaccination of the general population in 2009, government support of HPV vaccination programs was increased in many countries. However, this policy was not implemented in Korea due to perceived low cost-effectiveness. Thus, the aim of this study was to analyze the cost-utility of HPV vaccination programs targeted to high risk populations as compared to vaccination programs for the general population. Materials and Methods: Each study population was set to 100,000 people in a simulation study to determine the incremental cost-utility ratio (ICUR), then standard prevalence rates, cost, vaccination rates, vaccine efficacy, and the Quality-Adjusted Life-Years (QALYs) were applied to the analysis. In addition,

show abstract

Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium

Abstract: Extending HPV vaccination to females post-sexual debut could lead to a substantial reduction in CC-related burden and would be cost-effective in Belgium.

Cited by 18 publications

References 34 publications

The cost–effectiveness of HPV vaccination in addition to screening: a Dutch perspective

The cost–effectiveness of HPV vaccination in addition to screening: a Dutch perspective

The impact on women’s health and the cervical cancer screening budget of primary HPV screening with dual-stain cytology triage in Belgium

Cost-Effectiveness Analysis of HPV Vaccination: Comparing the General Population with Socially Vulnerable Individuals

Contact Info

Product

Resources

About